List view / Grid view
As part of its planned £2.5 billion acquisition of Chinook…
As part of its planned £2.5 billion acquisition of Chinook Therapeutics, Novartis will gain access to a targeted biologic for a rare kidney disease.
![Sandoz company logo on office building in Warsaw city centre [Credit: Konektus Photo/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Sandoz-2-e1661424920546-300x278.jpg)
![Sandoz company logo on office building in Warsaw city centre [Credit: Konektus Photo/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Sandoz-2-e1661424920546.jpg)
A spin-off from parent company Novartis aims to set Sandoz…
A spin-off from parent company Novartis aims to set Sandoz up as the premier European generics company.
Phase II trial data suggests ensovibep (MP0420) significantly reduces SARS-CoV-2…
Phase II trial data suggests ensovibep (MP0420) significantly reduces SARS-CoV-2 viral load and reduces hospitalisation and death due to COVID-19.
As companies continue to collaborate and share their expertise to…
As companies continue to collaborate and share their expertise to develop therapeutics targeting a wide range of diseases, European Pharmaceutical Review explores the aims of the most recent partnerships.
Novartis reportedly knew of discrepancies in the Zolgensma data it…
Novartis reportedly knew of discrepancies in the Zolgensma data it had submitted to the FDA but delayed informing regulators so has announced alterations to its processes.
Novartis has announced long-term study results supporting the positive safety…
Novartis has announced long-term study results supporting the positive safety and efficacy of Revolade in adults with chronic/persistent immune thrombocytopenia...
